We are a BioPharma leader focused on helping to address the unmet medical needs of patients with serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis. Over the past decade, we have delivered 14 new products to patients with serious diseases. Four of these products are biologic products.
The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
Closing share price
|FY, 2015||FY, 2014||FY, 2013|
|$16.6 B||$15.9 B||$16.4 B|
|$1.63 B||$2.03 B||$2.58 B|